Polyclonal Antibodies Market size is poised to reach USD 26 Billion by the end of 2036, growing at a CAGR of 8% during the forecast timeframe, i.e., 2024-2036. In the year 2023, the industry size of the polyclonal antibodies revenue share was USD 10 Billion. The market expansion is due to the projected need for therapeutic applications, as polyclonal antibodies find extensive use in therapeutic applications, notably in the development of antivenom and immunoglobulin therapies, which can help in preventing hemolytic disease in newborns while modifying inflammatory reactions.
According to a report, about 25% of newborns suffer from hemolytic disease of the newborns (HDN), which requires transfusion. Due to this, this industry is expected to witness a substantial growth rate in the forecasted years.
In addition, adopting polyclonal antibodies is particularly important in cases where the multifaceted nature of diseases necessitates a comprehensive immune response. For instance, in antivenom therapy, polyclonal antibodies are harnessed to neutralize the venom components of various snake species effectively.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
8% |
|
Base Year Market Size (2023) |
USD 10 Billion |
|
Forecast Year Market Size (2036) |
USD 26 Billion |
|
Regional Scope |
|
Type (Human Source, Animal Source)
The human source segment in the polyclonal antibodies market is estimated to gain revenue of about 54% by 2036. The segment influence can be attributed to the pursuit of enhanced immunogenicity and specificity, as human-derived antibodies have a natural advantage in clinical and therapeutic applications as they are less likely to provoke an immune response when tested on humans.
Additionally, this characteristic is particularly crucial in therapeutic interventions, ensuring greater safety and reducing the risk of adverse reactions. Human-derived polyclonal antibodies offer reduced cross-reactivity and improved safety profiles, making them increasingly attractive for therapeutic use. Cross-reactivity, often encountered with animal-derived antibodies, can lead to unintended side effects.
By sourcing antibodies from humans, the likelihood of unwanted interactions and adverse events is minimized, aligning with the stringent safety requirements in clinical settings. The increasing emphasis on personalized medicine has emerged as a significant growth driver for human-sourced polyclonal antibodies.
End Users (Hospitals, Diagnostic Laboratories, Biotechnology Companies)
The hospital segment in the polyclonal antibodies market is expected to garner a tremendous share by the end of 2036. As polyclonal antibodies are highly used in hospitals for therapeutic purposes, particularly in immunotherapy, because they play a crucial role in modulating immune responses, this makes them a valuable component in the treatment of various diseases, including certain cancers and autoimmune disorders. The application of polyclonal antibodies in immunotherapy widens the therapeutic options available to hospitals for managing complex medical conditions.
A clinical trial review reported a 30% improvement in overall response rates in cancer patients treated with immunotherapies incorporating polyclonal antibodies. Advancements in point-of-care testing within hospitals are facilitated by the use of polyclonal antibodies. The rapid and reliable results obtained through point-of-care tests contribute to timely diagnosis and treatment decisions. The flexibility of polyclonal antibodies in various testing formats enhances their applicability in point-of-care settings, supporting hospitals in providing efficient and patient-centric healthcare services.
Our in-depth analysis of the global polyclonal antibodies market includes the following segments:
|
Type |
|
|
End-user |
|
|
Source |
|
|
Product Type |
|
|
Application |
|
APAC Market Forecast
The polyclonal antibodies market in the Asia Pacific region is set to hold the largest share of about 47% by the end of 2036. This sector is poised to propel in the region and is expected to drive on account of the extensive use of polyclonal antibodies in immunohistochemistry (IHC), a technique crucial for the examination of tissue samples. Hospitals leverage IHC for the diagnosis of various cancers and pathological conditions.
Moreover, the versatility of polyclonal antibodies in recognizing multiple antigens makes them invaluable in IHC applications, enabling hospitals to obtain comprehensive and detailed information from tissue specimens. Polyclonal antibodies play a crucial role in hospitals during infectious disease outbreaks. They are utilized for the rapid development of diagnostic tests and potential therapeutic interventions. During the Zika virus outbreak, hospitals incorporating polyclonal antibodies in diagnostic assays reported a 20% faster identification of infected individuals compared to hospitals using alternative testing methods.
North American Market Statistics
The North American region will also encounter a huge impact on the polyclonal antibodies market size expansion in the coming years and will hold the second position owing to the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders, which would drive the need for advanced diagnostic tools and targeted therapeutic interventions, where polyclonal antibodies will find extensive applications.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?